Machine Learning-Based Pathomics Model to Predict the Prognosis in Clear Cell Renal Cell Carcinoma

被引:0
作者
Li, Xiangyun [1 ]
Yang, Xiaoqun [1 ]
Yang, Xianwei [1 ]
Xie, Xin [2 ]
Rui, Wenbin [2 ]
He, Hongchao [2 ,3 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Ruijin Hosp, Sch Med, Dept Pathol, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Ruijin Hosp, Sch Med, Dept Urol, 197 Ruijin Er Rd, Shanghai 200025, Peoples R China
[3] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
关键词
clear cell renal cell carcinoma; pathomics; machine learning; HE staining; prognosis; CANCER; GENE; PROGRESSION; INTEGRATION; PATHWAY;
D O I
10.1177/15330338241307686
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Clear cell renal cell carcinoma (ccRCC) is a highly lethal urinary malignancy with poor overall survival (OS) rates. Integrating computer vision and machine learning in pathomics analysis offers potential for enhancing classification, prognosis, and treatment strategies for ccRCC. This study aims to create a pathomics model to predict OS in ccRCC patients. In this study, data from ccRCC patients in the TCGA database were used as a training set, with clinical data serving as a validation set. Pathological features were extracted from H&E-stained slides using PyRadiomics, and a pathomics model was constructed using the non-negative matrix factorization (NMF) algorithm. The model's predictive performance was assessed through Kaplan-Meier (KM) survival curves and Cox regression analysis. Additionally, differential gene expression, gene ontology (GO) enrichment analysis, immune infiltration, and mutational analysis were conducted to investigate the underlying biological mechanisms. A total of 368 pathomics features were extracted from H&E-stained slides of ccRCC patients, and a pathomics model comprising two subtypes (Cluster 1 and Cluster 2) was successfully constructed using the NMF algorithm. KM survival curves and Cox regression analysis revealed that Cluster 2 was associated with worse OS. A total of 76 differential genes were identified between the two subtypes, primarily involving extracellular matrix organization and structure. Immune-related genes, including CTLA4, CD80, and TIGIT, were highly expressed in Cluster 2, while the VHL and PBRM1 genes, along with mutations in the PI3K-Akt, HIF-1, and MAPK signaling pathways, exhibited mutation rates exceeding 40% in both subtypes. The machine learning-based pathomics model effectively predicts the OS of ccRCC patients and differentiates between subtypes. The critical roles of the immune-related gene CTLA4 and the PI3K-Akt, HIF-1, and MAPK signaling pathways offer new insights for further research on the molecular mechanisms, diagnosis, and treatment strategies for ccRCC.
引用
收藏
页数:16
相关论文
共 75 条
[1]   Molecular and Metabolic Basis of Clear Cell Carcinoma of the Kidney [J].
Akhtar, Mohammed ;
Al-Bozom, Issam A. ;
Al Hussain, Turki .
ADVANCES IN ANATOMIC PATHOLOGY, 2018, 25 (03) :189-196
[2]   Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naive patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B) [J].
Atkins, Michael B. ;
Jegede, Opeyemi A. ;
Haas, Naomi B. ;
McDermott, David F. ;
Bilen, Mehmet A. ;
Stein, Mark ;
Sosman, Jeffrey A. ;
Alter, Robert ;
Plimack, Elizabeth R. ;
Ornstein, Moshe C. ;
Hurwitz, Michael ;
Peace, David J. ;
Signoretti, Sabina ;
Denize, Thomas ;
Cimadamore, Alessia ;
Wu, Catherine J. ;
Braun, David ;
Einstein, David ;
Catalano, Paul J. ;
Hammers, Hans .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (03)
[3]   PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis [J].
Badoiu, Silviu Constantin ;
Greabu, Maria ;
Miricescu, Daniela ;
Stanescu-Spinu, Iulia-Ioana ;
Ilinca, Radu ;
Balan, Daniela Gabriela ;
Balcangiu-Stroescu, Andra-Elena ;
Mihai, Doina-Andrada ;
Vacaroiu, Ileana Adela ;
Stefani, Constantin ;
Jinga, Viorel .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (09)
[4]   Integrative analysis and risk model construction for super-enhancer-related immune genes in clear cell renal cell carcinoma [J].
Bi, Zhenyu ;
Zhou, Jinghao ;
Ma, Yan ;
Guo, Qingxin ;
Ju, Boyang ;
Zou, Haoran ;
Zhan, Zuhao ;
Yang, Feihong ;
Du, Han ;
Gan, Xiuguo ;
Song, Erlin .
ONCOLOGY LETTERS, 2024, 27 (05)
[5]   Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial [J].
Brown, Janet E. ;
Royle, Kara-Louise ;
Gregory, Walter ;
Ralph, Christy ;
Maraveyas, Anthony ;
Din, Omar ;
Eisen, Timothy ;
Nathan, Paul ;
Powles, Tom ;
Griffiths, Richard ;
Jones, Robert ;
Vasudev, Naveen ;
Wheater, Matthew ;
Hamid, Abdel ;
Waddell, Tom ;
McMenemin, Rhona ;
Patel, Poulam ;
Larkin, James ;
Faust, Guy ;
Martin, Adam ;
Swain, Jayne ;
Bestall, Janine ;
McCabe, Christopher ;
Meads, David ;
Goh, Vicky ;
Wah, Tze Min ;
Brown, Julia ;
Hewison, Jenny ;
Selby, Peter ;
Collinson, Fiona .
LANCET ONCOLOGY, 2023, 24 (03) :213-227
[6]   Metagenes and molecular pattern discovery using matrix factorization [J].
Brunet, JP ;
Tamayo, P ;
Golub, TR ;
Mesirov, JP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (12) :4164-4169
[7]   MFN2 suppresses the accumulation of lipid droplets and the progression of clear cell renal cell carcinoma [J].
Cai, Zhiduan ;
Luo, Wenjun ;
Wang, Haoran ;
Zhu, Rui ;
Yuan, Yaoji ;
Zhan, Xiangyu ;
Xie, Mengyuan ;
Zhuang, Haoquan ;
Chen, Haoyu ;
Xu, Yuyu ;
Li, Xiezhao ;
Liu, Leyuan ;
Xu, Guibin .
CANCER SCIENCE, 2024, 115 (06) :1791-1807
[8]   An Integrated Machine Learning Framework Identifies Prognostic Gene Pair Biomarkers Associated with Programmed Cell Death Modalities in Clear Cell Renal Cell Carcinoma [J].
Chen, Bohong ;
Zhou, Mingguo ;
Guo, Li ;
Huang, Haoxiang ;
Sun, Xinyue ;
Peng, Zihe ;
Wu, Dapeng ;
Chen, Wei .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2024, 29 (03)
[9]   Comprehensive analyses of solute carrier family members identify SLC12A2 as a novel therapy target for colorectal cancer [J].
Chen, Dan-yang ;
Zhang, Yang-yang ;
Nie, Hai-hang ;
Wang, Hai-zhou ;
Qiu, Pei-shan ;
Wang, Fan ;
Peng, Ya-nan ;
Xu, Fei ;
Zhao, Qiu ;
Zhang, Meng .
SCIENTIFIC REPORTS, 2024, 14 (01)
[10]   Predicting peritoneal recurrence in gastric cancer with serosal invasion using a pathomics nomogram [J].
Chen, Dexin ;
Lai, Jianbo ;
Cheng, Jiaxin ;
Fu, Meiting ;
Lin, Liyan ;
Chen, Feng ;
Huang, Rong ;
Chen, Jun ;
Lu, Jianping ;
Chen, Yuning ;
Huang, Guangyao ;
Yan, Miaojia ;
Ma, Xiaodan ;
Li, Guoxin ;
Chen, Gang ;
Yan, Jun .
ISCIENCE, 2023, 26 (03)